HOME >> MEDICINE >> NEWS
Tamoxifen for prevention of breast cancer encouraging results but risks still unclear

Early findings from a randomised trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in this week's issue of THE LANCET. Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk to benefit ratio of tamoxifen as a preventative strategy for breast cancer.

Tamoxifen is well known in its effect to decrease recurrence of (and death from) breast cancer; however, three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear.

Jack Cuzick from Cancer Research UK, lead investigator of the International Breast Cancer Intervention Study (IBIS-I) and colleagues undertook a double-blind placebo-controlled randomised trial of tamoxifen, 20 mg/day for 5 years, in around 7000 women from the UK, Europe, Australia and New Zealand who were aged 3570 years and who were at an increased risk of breast cancer (eg. They had a Family history of the disease or had a benign lesion associated with an increased risk of breast cancer).

The frequency of breast cancer was reduced by a third among Women given tamoxifen (69 breast cancers in 3578 women in the tamoxifen group and 101 breast cancers in 3566 in the placebo group). Endometrial cancer--considered to be increased by tamoxifen use--was doubled in the tamoxifen group (11 instances compared with 5 in the control group), but this increase was not statistically significant, and all cases were localised (stage 1) and curable by hysterectomy.

However, tamoxifen use was associated with more than a doubling in the risk of blood-clotting complications, especially after surgery or long periods of immobilisation. The investigators comment that the incre
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
12-Sep-2002


Page: 1 2

Related medicine news :

1. Tamoxifens risks similar in African American and white women
2. Tamoxifen and estrogen have similar effects on the brain
3. Tamoxifen found to increase risk of endometrial cancer
4. Views Of Tamoxifen And Synthetic Estrogen In Action Provide Clues For Designing Better Drugs
5. International breast cancer prevention study launches in the United States and Canada
6. Cavity prevention tips for pre-school age children
7. HIV and ID doctors oppose ideologically driven STI prevention policies
8. School-based smoking prevention programs ineffective
9. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
10. Mount Sinai stroke prevention trial published in JAMA
11. New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding

Post Your Comments:
(Date:11/22/2014)... 2014 Recently, UWDress.com, a successful wedding dress ... guest attire in order to prepare for the wedding ... to 70% off. , UWDress.com is a reliable company ... beautiful, especially the new items -- formal wedding guest attire. ... current market, including superstar and princess. As one of the ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) ... allegedly developed Type 2 diabetes due to its use ... now underway in U.S. District Court, District of South ... the litigation will convene its next Status Conference on ... Lead Counsel for Plaintiffs and Defendants to meet and ...
(Date:11/22/2014)... The Sports Conflict Institute is pleased to ... team of conflict resolution professionals. Baroff comes to SCI as ... has over 30 years experience as an arbitrator, educator, and ... to connect with SCI and bring my conflict resolution skills ... with a complete sports focus,” says Baroff. , “Roy has ...
Breaking Medicine News(10 mins):Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3
(Date:11/21/2014)... WOODLANDS, Texas , Nov. 21, 2014  Lexicon ... the pricing of its previously announced underwritten public offering ... to an effective shelf registration statement. The offering will ... public offering price of $1.005 per share.  Lexicon has ... up to 7,462,687 additional shares of common stock.  All ...
(Date:11/18/2014)... 2014  NxStage ® Medical Inc. (Nasdaq: ... innovative dialysis products , today announced the ... for the in-center, hemodialysis market.  Streamline Express features ... to reduce the amount of labor required for ... touch point contamination sites.  The dialyzer enables achievement ...
(Date:11/18/2014)... 2014  Sanguine Biosciences – a biotechnology company ... recruitment – will use its proprietary mobile application ... Inc. find and recruit people diagnosed with Congenital ... to participate in voluntary research, which will be ... hopefully aid in informing the development of potential ...
Breaking Medicine Technology:Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
Cached News: